Tonix Pharmaceuticals Holding Corp. (TNXP) Stock Forecast
TNXP analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 3 analysts
- Price target
- $44.50 average of analyst targets
- Upside to target
- +636.8% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-2.52
- 52-week range
- $6.04 – $20.35
TNXP analyst ratings
3 analystsNumber of analysts at each rating.
TNXP price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TNXP earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$2.33 | −$2.51 | −$2.15 | −$3.70 | +37.0% | 2 |
| Current fiscal year (2026) | −$9.95 | −$10.40 | −$9.50 | −$14.68 | +32.2% | 2 |
| Next fiscal year (2027) | −$7.88 | −$8.25 | −$7.50 | −$9.95 | +20.8% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TNXP revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $15.9M | $14.6M | $19.0M | +382.4% | 4 |
| Current fiscal year (2026) | $55.0M | $51.0M | $65.0M | +319.6% | 4 |
| Next fiscal year (2027) | $110.9M | $83.1M | $149.0M | +101.6% | 4 |
TNXP EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TNXP revenue: reported and forecast
TNXP EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$2.41 | −$2.33 | −$2.33 | −$2.33 | −$2.33 | −3.3% | 1 up · 0 down |
| Current fiscal year (2026) | −$10.10 | −$9.95 | −$9.95 | −$9.95 | −$9.95 | −1.5% | 1 up · 0 down |
| Next fiscal year (2027) | −$7.80 | −$7.88 | −$7.88 | −$7.88 | −$7.88 | +1.0% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TNXP earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; TNXP beat in 6 of 12.
What analysts expect from TNXP
3 analysts cover Tonix Pharmaceuticals; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $44.50, 636.8% above the latest close of $6.04. Analysts expect earnings of −$9.95 per share for 2026, +32.2% from a year earlier. For 2027 the average estimate is −$7.88 per share on revenue of $110.9 million. Tonix Pharmaceuticals beat the EPS estimate in 6 of the last 12 quarters.
Related: TNXP income statement, TNXP key metrics, TNXP chart. See the TNXP stock overview for the latest quote and news.
TNXP forecast FAQ
What is Tonix Pharmaceuticals's price target?
The average analyst price target for Tonix Pharmaceuticals is $44.50, 636.8% above the latest close of $6.04.
Is Tonix Pharmaceuticals a buy, hold or sell?
Of 3 analysts covering Tonix Pharmaceuticals, 3 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Tonix Pharmaceuticals's EPS forecast?
Analysts forecast −$9.95 per share for 2026 (range −$10.40 to −$9.50); for 2027 the estimate is −$7.88.
What is Tonix Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $55.0 million, growth of 319.6%; for 2027 it is $110.9 million.
When does Tonix Pharmaceuticals report earnings?
Tonix Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 before the market opens; the EPS estimate is $-2.52.
Does Tonix Pharmaceuticals usually beat earnings estimates?
Tonix Pharmaceuticals reported EPS at or above the analyst estimate in 6 of the last 12 quarters.